Crinetics Pharmaceuticals Inc (FRA:6Z4) Stock Price, Trades & News

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Financial Strength

7/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	26.98
Equity-to-Asset	0.91
Debt-to-Equity	0.04
Debt-to-EBITDA	-0.09
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	42.5	Distress Grey Safe
Beneish M-Score	17.05	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-3.4
	3-Year EBITDA Growth Rate	-19.3
	3-Year EPS without NRI Growth Rate	-16.1
	3-Year FCF Growth Rate	-22
	3-Year Book Growth Rate	20.9
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	19.77
	Future 3-5Y Total Revenue Growth Rate Estimate	264.59

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	77.92
	9-Day RSI	84.42
	14-Day RSI	84.42
	3-1 Month Momentum %	-13.28
	6-1 Month Momentum %	-0.5
	12-1 Month Momentum %	8.21

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	18.6
	Quick Ratio	18.56
	Cash Ratio	18.17
	Days Inventory	4640.98
	Days Sales Outstanding	63.38
	Days Payable	22909.59

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-21.1
	Shareholder Yield %	-4.24

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	98.89
	Operating Margin %	-3020.32
	Net Margin %	-2747.18
	EBITDA Margin %	-2997.49
	FCF Margin %	-2317.06
	OCF Margin %	-2287.43
	ROE %	-43.01
	ROA %	-38.94
	ROIC %	-498.35
	3-Year ROIIC %	-342.54
	ROC (Joel Greenblatt) %	-990.48
	ROCE %	-45.34
	Moat Score	5
	Tariff Resilience Score	7

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	463.31
	PB Ratio	6.9
	Price-to-Tangible-Book	6.9
	EV-to-EBIT	-13.99
	EV-to-Forward-EBIT	6.05
	EV-to-EBITDA	-14.09
	EV-to-Revenue	422.4
	EV-to-Forward-Revenue	113.14
	EV-to-FCF	-18.19
	Price-to-GF-Value	0.11
	Price-to-Net-Current-Asset-Value	7.35
	Price-to-Net-Cash	7.54
	Earnings Yield (Greenblatt) %	-7.15
	FCF Yield %	-4.73

Financials (Next Earnings Date:2026-08-04)

Annual Quarterly TTM

FRA:6Z4's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Crinetics Pharmaceuticals Inc Executives

Details

GF Value™: €640.84

FRA:6Z4

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with 6Z4. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	15.562
	EPS (TTM) (€)	-4.408
	Beta	0.4173
	3-Year Sharpe Ratio	0.57
	3-Year Sortino Ratio	1.43
	Volatility %	52.26
	14-Day RSI	84.42
	14-Day ATR (€)	2.274294
	20-Day SMA (€)	50.188
	12-1 Month Momentum %	8.21
	52-Week Range (€)	23 - 73.08
	Shares Outstanding (Mil)	105.84

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	3
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Crinetics Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Crinetics Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-06 16:30	In 111 days
Third quarter earnings results for 2026	2026-11-06	In 110 days
Second quarter earnings conference call for 2026	2026-08-04 16:30	In 17 days
Second quarter earnings results for 2026	2026-08-04	In 16 days
General meeting for 2026	2026-06-18 08:00	29.65 (+0.00%)
First quarter earnings conference call for 2026	2026-05-07 16:30	34.21 (+0.00%)
First quarter earnings results for 2026	2026-05-07	34.21 (+0.00%)
TD Cowen 46th Annual Health Care Conference,	2026-03-04 13:50	33.60 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-26 16:30	36.80 (+0.00%)
Annual report for 2025	2026-02-26	36.80 (+0.00%)

Show

Entries

Crinetics Pharmaceuticals Inc Frequently Asked Questions

What is Crinetics Pharmaceuticals Inc(FRA:6Z4)'s stock price today?

The current price of FRA:6Z4 is €70.90. The 52 week high of FRA:6Z4 is €73.08 and 52 week low is €23.00.

When is next earnings date of Crinetics Pharmaceuticals Inc(FRA:6Z4)?

The next earnings date of Crinetics Pharmaceuticals Inc(FRA:6Z4) is 2026-08-04.

Does Crinetics Pharmaceuticals Inc(FRA:6Z4) pay dividends? If so, how much?

Crinetics Pharmaceuticals Inc(FRA:6Z4) does not pay dividend.

Press Release

	Subject	Date
	$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESI, CRNX, SOLS, and PATK	2026-07-16
	Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders?	2026-07-14
	Are ESI, CRNX, SOLS Obtaining Fair Deals for their Shareholders?	2026-07-09
	$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)	2026-07-09
	Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX	2026-07-08
	Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders	2026-07-06
	CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders	2026-07-06
	Thinking about trading options or stock in Tesla, C3.ai, Macy's, Crinetics Pharmaceuticals, or Tractor Supply?	2023-09-12

10/Page

Articles on Crinetics Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.